Healthy female adults
Conditions
Interventions
Ingestion of the test food (21 drops/day) for twelve weeks.
Ingestion of the placebo food (21 drops/day) for twelve weeks.
Sponsors
CPCC Company Limited
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) Healthy female subjects ranging in age from 20 to 64, at informed consent. (2) Subjects who feel their skin dryness, skin roughness, and so on. (3) Subjects who can give informed consent to partake in this trial after being provided with an explanation of the protocol detail.
Exclusion criteria
Exclusion criteria: Subjects - - (1) who take steadily (over 3 times a week) in affecting health-specific/functional/supplementary/health foods, (2) who have taken affecting medicines and quasi-ones (e.g., skin medicine for external use), over 3 times a week, and have any difficulty in refraining from taking them, (3) with excessive suntan, or planning to tan on trips, events, etc., (4) planning to change their cosmetics, (5) planning to newly begin their skin cares, (6) suffering from some kind of skin disease (e.g., atopic dermatitis), (7) having a bruise and/or a hurt near the skin-measuring position, (8) who are now under a specific care near the skin-measuring position (e.g., facial treatment, electric facial, peeling, body care, laser therapy, and hair removal) at an outside agency, (9) with excessive alcohol intake, (10) having mushrooms, over 5 days a week, (11) having livers, over 5 days a week, (12) being poor at mushrooms, (13) having their skin roughness due to pollinosis, (14) who realized being in a failing skin condition by menstruation, (15) having an irregular life rhythm with irregular shift work or midnight one, (16) being under other clinical tests with medicine or health food, or partook in those within four weeks to this trial, or planning to join those after giving informed consent, (17) planning to change their shapes of eyelashes/eyebrows, (18) having previous/current medical history of severe cardiac, hepatic, renal or digestive diseases, (19) with pregnancy, possibly one, or lactating, (20) with drug and food allergy, (21) who donated over 0.2 L of their blood and/or blood components within a month to this trial, (22) who donated their whole blood (0.4 L) within the last four months to this trial, (23) who will be collected in total of their blood (0.8 L) within the last twelve months, after adding the blood amounts planning to be sampled in this trial, (24) being determined as ineligible for participation, judging from the principal/sub investigator - - .
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Moisture-retention function transcutaneous moisture-evaporating capacity (left temple, and left forearm inside (2P)), and stratum corneum moisture-binding capacity (left temple, and left forearm inside (2P)) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Skin viscoelasticity (left temple, and left forearm inside (2P)) 2. VISIA TM Evolution (blotch, wrinkle, pores, color irregularity, hiding blotch, porphyrin, melanin-index, and hemoglobin-index) 3. Skin questionnaire 4. Oxidative stress degree test (thiobarbituric acid-reactive substances) 5. Blood ergothioneine | — |
Countries
Japan
Contacts
Public ContactMakoto Ichinohe
CPCC Company Limited Clinical Planning Department
Outcome results
None listed